The U.S. Food and Drug Administration approved Amgen's combination therapy of Lumakras and Vectibix to treat advanced colorectal cancer in adults with specific KRAS and EGFR gene mutations. The treatment is for patients whose cancer has spread despite prior chemotherapy. The approval is supported by a late-stage study showing the therapy extended progression-free survival to 5.6 months, compared to two months with standard care.

Additionally, the FDA approved Qiagen's diagnostic device to identify eligible patients for this treatment. Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths, highlighting the importance of such advancements in treatment.